Aligos Therapeutics (NASDAQ:ALGS) Shares Up 4.9% – What’s Next?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares were up 4.9% during mid-day trading on Wednesday . The company traded as high as $7.84 and last traded at $7.68. Approximately 19,208 shares were traded during trading, a decline of 35% from the average daily volume of 29,566 shares. The stock had previously closed at $7.32.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Aligos Therapeutics in a research note on Friday, September 20th.

Aligos Therapeutics Trading Up 10.6 %

The business’s 50-day simple moving average is $11.74 and its two-hundred day simple moving average is $14.84. The company has a market capitalization of $24.38 million, a PE ratio of -0.37 and a beta of 2.16.

Aligos Therapeutics (NASDAQ:ALGS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative return on equity of 110.59% and a negative net margin of 1,100.48%. The firm had revenue of $1.06 million during the quarter. During the same period in the prior year, the company posted ($10.75) EPS. On average, analysts forecast that Aligos Therapeutics, Inc. will post -8.2 EPS for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Institutional investors have recently modified their holdings of the stock. Opaleye Management Inc. bought a new stake in shares of Aligos Therapeutics in the 4th quarter valued at approximately $861,000. Acadian Asset Management LLC boosted its holdings in Aligos Therapeutics by 17.6% in the first quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after purchasing an additional 98,628 shares during the period. Finally, Armistice Capital LLC raised its holdings in shares of Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).